Recent Updates
Recently added Catalysts
CRIS Positive Sentiment

von Roemeling C., Emavusertib improved response to anti-PD-1 AACR 2024

Tuesday, April 16, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article highlights the positive results of Emavusertib (CA-4948) in improving responses to anti-PD-1 therapy. This development suggests a promising advancement in treatment options for patients, particularly in oncology. The findings may lead to better patient outcomes in clinical trials and future therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Emavusertib shows improved response to anti-PD-1 therapy.
  • Potential for enhanced treatment options in oncology.
  • Positive implications for patient outcomes in clinical settings.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What is Emavusertib?

Emavusertib, also known as CA-4948, is a drug being studied for its efficacy in cancer treatment.

How does Emavusertib relate to anti-PD-1 therapy?

Emavusertib has shown improved responses when used alongside anti-PD-1 therapy in clinical trials.

What are the implications of this study?

The study suggests that Emavusertib may enhance treatment outcomes for patients undergoing anti-PD-1 therapy.

Is Emavusertib currently available for patients?

The article does not specify availability; it focuses on clinical trial results.

ShareAdd on Google
Tags: CRIS Viatris Investor Conferences Healthcare Emavusertib anti-PD-1 oncology clinical trials
Last updated: Apr 16, 2024

Biotech snapshot

Cash runway
$5M liquidity · $3M/mo burn
~1 mo
High dilution risk
Lead asset
EmavusertibPhase 2
Chronic Lymphocytic Leukemia →